Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study



Kerber, Romy, Lorenz, Eva, Duraffour, Sophie, Sissoko, Daouda, Rudolf, Martin, Jaeger, Anna, Cisse, Sekou Ditinn, Camara, Alseny-Modet, Miranda, Osvaldo, Castro, Carlos M
et al (show 63 more authors) (2019) Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study. JOURNAL OF INFECTIOUS DISEASES, 220 (2). pp. 195-202.

[thumbnail of Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retr.pdf] Text
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retr.pdf - Published Version

Download (485kB) | Preview

Abstract

<h4>Background</h4>In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus-specific reverse transcription-polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis.<h4>Methods</h4>To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome.<h4>Results</h4>The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors.<h4>Conclusions</h4>Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.

Item Type: Article
Uncontrolled Keywords: Filovirus, Ebola virus disease, Favipiravir, Guinea, epidemic, mobile laboratory
Depositing User: Symplectic Admin
Date Deposited: 06 Jul 2020 11:27
Last Modified: 18 Jan 2023 23:49
DOI: 10.1093/infdis/jiz078
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3090526